Skip to main content
. Author manuscript; available in PMC: 2025 Aug 25.
Published in final edited form as: Am J Hematol. 2017 Nov 27;93(2):277–285. doi: 10.1002/ajh.24972

FIGURE 1.

FIGURE 1

(A) depicts the percentage of change in spleen volume during therapy. Of the 12 patients with baseline splenomegaly palpable >5 cm below costal margin, 9 (64%) showed clinical improvement with >50% reduction of spleen volume when treated with AZA 1 RUX, at a median time of 1.8 months (range, 0.7–7.3 months), including 4 patients with 100% decrease from baseline. One patient achieved 45% reduction of splenomegaly, while 2 patients did not have any clinical improvement of spleen volume. (B) Overall survival, per diagnosis cohort, of patients with MDS/MPN treated with ruxolitinib and azacytidine. Kaplan–Meier estimates. (C) Overall survival of patients with MDS/MPN who have achieved clinical response in general compared to those who had no response; Kaplan–Meier analysis. mOS: Median overall survival [Color figure can be viewed at wileyonlinelibrary.com]